613 related articles for article (PubMed ID: 33988035)
1. Nanomedicine for the poor: a lost cause or an idea whose time has yet to come?
Uskoković V
Nanomedicine (Lond); 2021 Jun; 16(14):1203-1218. PubMed ID: 33988035
[TBL] [Abstract][Full Text] [Related]
2. Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine.
Milane L; Amiji M
Drug Deliv Transl Res; 2021 Aug; 11(4):1309-1315. PubMed ID: 33512669
[TBL] [Abstract][Full Text] [Related]
3. COVID-19 vaccines and nanomedicine.
Shapiro RS
Int J Dermatol; 2021 Sep; 60(9):1047-1052. PubMed ID: 34089534
[TBL] [Abstract][Full Text] [Related]
4. SARS-COV-2 Vaccines: What Indicators are Associated with the Worldwide Distribution of the First Doses.
Sobral MFF; Bezerra de Oliveira BR; Gomes da Penha Sobral AI; Monteiro Marinho ML; Duarte GB; de Souza Melo A
Inquiry; 2021; 58():469580211060184. PubMed ID: 34823403
[TBL] [Abstract][Full Text] [Related]
5. Assessing the impacts of COVID-19 vaccination programme's timing and speed on health benefits, cost-effectiveness, and relative affordability in 27 African countries.
Liu Y; Procter SR; Pearson CAB; Montero AM; Torres-Rueda S; Asfaw E; Uzochukwu B; Drake T; Bergren E; Eggo RM; Ruiz F; Ndembi N; Nonvignon J; Jit M; Vassall A
BMC Med; 2023 Mar; 21(1):85. PubMed ID: 36882868
[TBL] [Abstract][Full Text] [Related]
6. Application of Traditional Vaccine Development Strategies to SARS-CoV-2.
Rando HM; Lordan R; Lee AJ; Naik A; Wellhausen N; Sell E; Kolla L; ; Gitter A; Greene CS
mSystems; 2023 Apr; 8(2):e0092722. PubMed ID: 36861991
[TBL] [Abstract][Full Text] [Related]
7. COVID-19 vaccines and treatments nationalism: Challenges for low-income countries and the attainment of the SDGs.
Nhamo G; Chikodzi D; Kunene HP; Mashula N
Glob Public Health; 2021 Mar; 16(3):319-339. PubMed ID: 33317389
[TBL] [Abstract][Full Text] [Related]
8. Success of nano-vaccines against COVID-19: a transformation in nanomedicine.
Sarangi MK; Padhi S; Rath G; Nanda SS; Yi DK
Expert Rev Vaccines; 2022 Dec; 21(12):1739-1761. PubMed ID: 36384360
[TBL] [Abstract][Full Text] [Related]
9. Pandemic preparedness and COVID-19: an exploratory analysis of infection and fatality rates, and contextual factors associated with preparedness in 177 countries, from Jan 1, 2020, to Sept 30, 2021.
COVID-19 National Preparedness Collaborators
Lancet; 2022 Apr; 399(10334):1489-1512. PubMed ID: 35120592
[TBL] [Abstract][Full Text] [Related]
10. Nanomedicine for the SARS-CoV-2: State-of-the-Art and Future Prospects.
Varahachalam SP; Lahooti B; Chamaneh M; Bagchi S; Chhibber T; Morris K; Bolanos JF; Kim NY; Kaushik A
Int J Nanomedicine; 2021; 16():539-560. PubMed ID: 33519200
[TBL] [Abstract][Full Text] [Related]
11. Supply and delivery of vaccines for global health.
Excler JL; Privor-Dumm L; Kim JH
Curr Opin Immunol; 2021 Aug; 71():13-20. PubMed ID: 33845349
[TBL] [Abstract][Full Text] [Related]
12. COVAX and equitable access to COVID-19 vaccines.
Yoo KJ; Mehta A; Mak J; Bishai D; Chansa C; Patenaude B
Bull World Health Organ; 2022 May; 100(5):315-328. PubMed ID: 35521037
[TBL] [Abstract][Full Text] [Related]
13. The impact of national income and vaccine hesitancy on country-level COVID-19 vaccine uptake.
Moradpour J; Shajarizadeh A; Carter J; Chit A; Grootendorst P
PLoS One; 2023; 18(11):e0293184. PubMed ID: 37917650
[TBL] [Abstract][Full Text] [Related]
14. The impact of delayed access to COVID-19 vaccines in low- and lower-middle-income countries.
Duroseau B; Kipshidze N; Limaye RJ
Front Public Health; 2022; 10():1087138. PubMed ID: 36711400
[TBL] [Abstract][Full Text] [Related]
15. Ensuring the global COVID-19 vaccine equity: Universal vaccine access strategy in the context of low and-middle-income countries.
Parray AA; Yadav UN; Das A; Ali AM; Mollick S; Saha S; Mistry SK
Glob Public Health; 2022 Apr; 17(4):614-621. PubMed ID: 35050840
[No Abstract] [Full Text] [Related]
16. Determinants of access to the SARS-CoV-2 vaccine: a preliminary approach.
de Oliveira BRB; da Penha Sobral AIG; Marinho MLM; Sobral MFF; de Souza Melo A; Duarte GB
Int J Equity Health; 2021 Aug; 20(1):183. PubMed ID: 34391416
[TBL] [Abstract][Full Text] [Related]
17. COVID-19 Vaccine Diplomacy and Equitable Access to Vaccines Amid Ongoing Pandemic.
Sharun K; Dhama K
Arch Med Res; 2021 Oct; 52(7):761-763. PubMed ID: 33941393
[TBL] [Abstract][Full Text] [Related]
18. How has nanomedical innovation contributed to the COVID-19 vaccine development?
Figueiró Longo JP; Muehlmann LA
Nanomedicine (Lond); 2021 Jun; 16(14):1179-1181. PubMed ID: 33973802
[No Abstract] [Full Text] [Related]
19. Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis.
So AD; Woo J
BMJ; 2020 Dec; 371():m4750. PubMed ID: 33323376
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
